diabetic cardiomyopathy
Conditions
Interventions
FGF1, 
FGF2, 
FGF21, 
FGF23, 
TNFa, 
IL-1b, 
MCP-1, 
ICAM-1, 
VCAM-1, 
GLUT4
Acetyl-COA, 
b-oxidation, 
PPARg, 
PPARb, 
PPARa, 
Col1a1, 
col3a1, 
Sponsors
Changzhou First People's Hospital (The Third Affiliated Hospital of Soochow University)
Eligibility
Sex/Gender
All
Age
35 Years to 70 Years
Inclusion criteria
Inclusion criteria: The patients were hospitalized with T2DM in the Endocrinology Department of the Third Affiliated Hospital of Soochow University from April 2020 to June 2025, regardless of the duration of diabetes. The medical treatment consisted of oral anti-hyperglycemic agents and/or insulin therapy.
Exclusion criteria
Exclusion criteria: 1. A history of coronary artery disease, hypertension, valvular heart disease, or other type of cardiovascular disease; 2. A self-reported history of symptomatic micro- or macrovascular complications of diabetes (including nephropathy, neuropathy, retinopathy, peripheral vascular disease, and stroke); 3. Pregnancy; 4. Other significant comorbidities including malignancy, renal failure, thyroid dysfunction, or significant psychiatric illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiac ultrasound and ECT;SPE, SEN, ACC, AUC of ROC; | — |
Countries
China
Contacts
Public ContactLichan Tao
Changzhou First People's Hospital (The Third Hospital of Soochow University)
Outcome results
None listed